TaiMed Biologics Inc.
Research TaiMed Biologics Inc. (4147.TWO) on Bullrun: market cap TWD 16.54B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4147.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 16.54B
- Financial periodQ2 2026
- RevenueTWD 155.84M
- Net income-TWD 72.73M
- Free cash flowTWD 32.53M
- Gross margin50.7%
Valuation Snapshot
latest market cap is TWD 16.54B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 16.54B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About TaiMed Biologics Inc.
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TaiMed Biologics Inc.'s market cap?
TaiMed Biologics Inc.'s market capitalization is TWD 16.54B.
What does TaiMed Biologics Inc. do?
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment.